Stelexis Biosciences Inc.

Stelexis Biosciences Inc. is focused on relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes, with clinical interest centered on difficult-to-treat blood cancers that have limited treatment options after prior therapy.

• Relapsed/refractory AML
• Higher-risk MDS
• Hematologic malignancies

The sponsor’s research activity in this area reflects a therapeutic emphasis on oncology, particularly hematologic oncology and treatment-resistant disease.